- Alvimopan
- Alvimopan dihydrate
- JDTic
ADL5859 HClδ-opioid receptor agonist,selective |
Sample solution is provided at 25 µL, 10mM.
Quality Control & MSDS
- View current batch:
- Purity = 98.40%
- COA (Certificate Of Analysis)
- HPLC
- NMR (Nuclear Magnetic Resonance)
- MSDS (Material Safety Data Sheet)
- Datasheet
Chemical structure
Description | ADL5859 HCl is a selective agonist of δ-opioid receptor with Ki value of 0.84 nM. | |||||
Targets | δ-opioid receptor | |||||
IC50 | 0.84 nM (Ki) |
ADL5859 HCl Dilution Calculator
calculate
ADL5859 HCl Molarity Calculator
calculate
Cas No. | 850173-95-4 | SDF | Download SDF |
Chemical Name | N,N-diethyl-4-(5-hydroxyspiro[chromene-2,4"-piperidine]-4-yl)benzamide;hydrochloride | ||
Canonical SMILES | CCN(CC)C(=O)C1=CC=C(C=C1)C2=CC3(CCNCC3)OC4=C2C(=CC=C4)O.Cl | ||
Formula | C24H28N2O3.HCl | M.Wt | 428.95 |
Solubility | ≥21.45mg/mL in DMSO | Storage | Store at -20°C |
Physical Appearance | A solid | Shipping Condition | Evaluation sample solution : ship with blue ice.All other available size:ship with RT , or blue ice upon request |
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. |
Selective δ opioid receptor agonists are promising potential therapeutic agents for the treatment of various types of pain conditions. A spirocyclic derivative was identified as a promising hit through screening. ADL5859 is a potent, selective, and orally bioavailable δ opioid receptor agonist. In vitro: ADL5859 displayed subnanomolar binding affinity at the δ opioid receptor, potent δ agonist activity, and excellent opioid receptor selectivity. Moreover, ADL5859 showed weak inhibitory activity at the hERG channel (78 μM) [1]. In vivo: On the basis of its favorable profile in vitro, ADL5859 was tested in the rat Freund’s complete adjuvant (FCA) mechanical hyperalgesia assay. At the screening dose of 3 mg/kg po, ADL5859 produced 100% reversal of hyperalgesia in the inflamed paw. The oral ED50 of ADL5859 in the FCA mechanical hyperalgesia assay was 1.4 mg/kg. The antihyperalgesia produced by ADL5859 (3 mg/kg, po) was reversed by pretreatment with the δ opioid antagonist naltrindole (0.3 mg/kg sc), thus demonstrating a δ receptor mediated effect. Therefore, ADL5859 was selected as a clinical candidate for the treatment of pain [1]. Clinical trial: A clinical study has been conducted to investigate the efficacy and safety of ADL5859 and ADL5747 in participants with pain due to osteoarthritis of the knee, which was supposed to be finished in the middle of 2015.Reference:[1] Le Bourdonnec B, Windh RT, Ajello CW, Leister LK, Gu M, Chu GH, Tuthill PA, Barker WM, Koblish M, Wiant DD, Graczyk TM, Belanger S, Cassel JA, Feschenko MS, Brogdon BL, Smith SA, Christ DD, Derelanko MJ, Kutz S, Little PJ, DeHaven RN, DeHaven-Hudkins DL, Dolle RE. Potent, orally bioavailable delta opioid receptor agonists for the treatment of pain: discovery of N,N-diethyl-4-(5-hydroxyspiro[chromene-2,4"-piperidine]-4-yl)benzamide (ADL5859). J Med Chem. 2008;51(19):5893-6.